ARCHIVES

Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.

This article is from The Cancer Letter archive.

Vol. 30 No. 18 | April 30, 2004

Download PDF Visit The Full Archive

Related Articles

FDA Proposes New Nonclinical Lab Regs

November 26, 1976

Ruffin Sworn In As Director, NIH Minority Health Center.

January 12, 2001

Angiogenesis Inhibitor In Phase III Trials For Metastatic Colorectal Cancer

September 26, 2003

FDA, NCI Near Agreement On Handling INDs

January 28, 1977

FDA’s Kweder cites Society of Professional Journalists’ Code of Ethics–incorrectly, SPJ says.

March 4, 2005

New Research Training Act May Permit NCI To Help fill Clinical Gaps In Radiotherapy, Medical Oncology

July 26, 1974